Pro Share Advisors LLC Genmab A/S Transaction History

Pro Share Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$30.95 - $39.68 $204,517 - $262,205	-6,608 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$35.87 - $47.12 $132,073 - $173,495	-3,682 Reduced 35.78%	6,608 $261,000
Q3 2021 Nov 12, 2021	BUY	$41.55 - $48.72 $70,011 - $82,093	1,685 Added 19.58%	10,290 $450,000
Q2 2021 Aug 13, 2021	BUY	$32.88 - $44.57 $65,036 - $88,159	1,978 Added 29.85%	8,605 $351,000
Q1 2021 May 14, 2021	SELL	$30.92 - $44.4 $13,357 - $19,180	-432 Reduced 6.12%	6,627 $218,000
Q4 2020 Feb 09, 2021	BUY	$33.66 - $40.76 $5,217 - $6,317	155 Added 2.25%	7,059 $287,000
Q3 2020 Nov 13, 2020	BUY	$33.07 - $38.68 $228,315 - $267,046	6,904 New	6,904 $253,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.